US20210196123A1 - Detecting potential health risks using nanorobotics - Google Patents
Detecting potential health risks using nanorobotics Download PDFInfo
- Publication number
- US20210196123A1 US20210196123A1 US17/202,314 US202117202314A US2021196123A1 US 20210196123 A1 US20210196123 A1 US 20210196123A1 US 202117202314 A US202117202314 A US 202117202314A US 2021196123 A1 US2021196123 A1 US 2021196123A1
- Authority
- US
- United States
- Prior art keywords
- user
- electronic signal
- nanite
- potential health
- health risk
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 230000036541 health Effects 0.000 title claims abstract description 56
- 238000000034 method Methods 0.000 claims abstract description 58
- 238000006243 chemical reaction Methods 0.000 claims abstract description 42
- 238000004891 communication Methods 0.000 claims description 22
- 239000000126 substance Substances 0.000 claims description 20
- 239000003814 drug Substances 0.000 claims description 18
- 229940079593 drug Drugs 0.000 claims description 18
- 230000009471 action Effects 0.000 claims description 16
- 238000004590 computer program Methods 0.000 claims 1
- 239000013076 target substance Substances 0.000 abstract description 3
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 10
- 238000001514 detection method Methods 0.000 description 7
- 230000006870 function Effects 0.000 description 7
- 239000013566 allergen Substances 0.000 description 5
- 230000001413 cellular effect Effects 0.000 description 5
- 235000012000 cholesterol Nutrition 0.000 description 5
- 230000007246 mechanism Effects 0.000 description 5
- 238000012544 monitoring process Methods 0.000 description 5
- 239000000758 substrate Substances 0.000 description 5
- 231100000252 nontoxic Toxicity 0.000 description 4
- 230000003000 nontoxic effect Effects 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- 206010020751 Hypersensitivity Diseases 0.000 description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 3
- 239000003054 catalyst Substances 0.000 description 3
- 229940088598 enzyme Drugs 0.000 description 3
- 239000008103 glucose Substances 0.000 description 3
- 239000008101 lactose Substances 0.000 description 3
- 238000011282 treatment Methods 0.000 description 3
- UCTWMZQNUQWSLP-VIFPVBQESA-N (R)-adrenaline Chemical compound CNC[C@H](O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-VIFPVBQESA-N 0.000 description 2
- 229930182837 (R)-adrenaline Natural products 0.000 description 2
- 102100026189 Beta-galactosidase Human genes 0.000 description 2
- 102000015081 Blood Coagulation Factors Human genes 0.000 description 2
- 108010039209 Blood Coagulation Factors Proteins 0.000 description 2
- 108010059881 Lactase Proteins 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 206010052428 Wound Diseases 0.000 description 2
- 230000007815 allergy Effects 0.000 description 2
- 108010005774 beta-Galactosidase Proteins 0.000 description 2
- 239000003114 blood coagulation factor Substances 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 229960005139 epinephrine Drugs 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 229940116108 lactase Drugs 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 238000002483 medication Methods 0.000 description 2
- 238000010295 mobile communication Methods 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 244000052769 pathogen Species 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 description 1
- 208000031220 Hemophilia Diseases 0.000 description 1
- 208000009292 Hemophilia A Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 208000035150 Hypercholesterolemia Diseases 0.000 description 1
- 208000013016 Hypoglycemia Diseases 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 201000010538 Lactose Intolerance Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 208000030961 allergic reaction Diseases 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 235000019219 chocolate Nutrition 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 230000006855 networking Effects 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 230000007096 poisonous effect Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/0002—Remote monitoring of patients using telemetry, e.g. transmission of vital signals via a communication network
- A61B5/0015—Remote monitoring of patients using telemetry, e.g. transmission of vital signals via a communication network characterised by features of the telemetry system
- A61B5/0022—Monitoring a patient using a global network, e.g. telephone networks, internet
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/07—Endoradiosondes
- A61B5/073—Intestinal transmitters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/145—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue
- A61B5/14546—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue for measuring analytes not otherwise provided for, e.g. ions, cytochromes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/74—Details of notification to user or communication with user or patient ; user input means
- A61B5/746—Alarms related to a physiological condition, e.g. details of setting alarm thresholds or avoiding false alarms
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N27/00—Investigating or analysing materials by the use of electric, electrochemical, or magnetic means
- G01N27/26—Investigating or analysing materials by the use of electric, electrochemical, or magnetic means by investigating electrochemical variables; by using electrolysis or electrophoresis
- G01N27/28—Electrolytic cell components
- G01N27/30—Electrodes, e.g. test electrodes; Half-cells
- G01N27/327—Biochemical electrodes, e.g. electrical or mechanical details for in vitro measurements
- G01N27/3275—Sensing specific biomolecules, e.g. nucleic acid strands, based on an electrode surface reaction
- G01N27/3278—Sensing specific biomolecules, e.g. nucleic acid strands, based on an electrode surface reaction involving nanosized elements, e.g. nanogaps or nanoparticles
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H40/00—ICT specially adapted for the management or administration of healthcare resources or facilities; ICT specially adapted for the management or operation of medical equipment or devices
- G16H40/60—ICT specially adapted for the management or administration of healthcare resources or facilities; ICT specially adapted for the management or operation of medical equipment or devices for the operation of medical equipment or devices
- G16H40/67—ICT specially adapted for the management or administration of healthcare resources or facilities; ICT specially adapted for the management or operation of medical equipment or devices for the operation of medical equipment or devices for remote operation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B2560/00—Constructional details of operational features of apparatus; Accessories for medical measuring apparatus
- A61B2560/02—Operational features
- A61B2560/0204—Operational features of power management
- A61B2560/0214—Operational features of power management of power generation or supply
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B2560/00—Constructional details of operational features of apparatus; Accessories for medical measuring apparatus
- A61B2560/02—Operational features
- A61B2560/0266—Operational features for monitoring or limiting apparatus function
- A61B2560/028—Arrangements to prevent overuse, e.g. by counting the number of uses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B2562/00—Details of sensors; Constructional details of sensor housings or probes; Accessories for sensors
- A61B2562/02—Details of sensors specially adapted for in-vivo measurements
- A61B2562/0285—Nanoscale sensors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/145—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue
- A61B5/1468—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue using chemical or electrochemical methods, e.g. by polarographic means
- A61B5/1473—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue using chemical or electrochemical methods, e.g. by polarographic means invasive, e.g. introduced into the body by a catheter
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/41—Detecting, measuring or recording for evaluating the immune or lymphatic systems
- A61B5/411—Detecting or monitoring allergy or intolerance reactions to an allergenic agent or substance
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/48—Other medical applications
- A61B5/4836—Diagnosis combined with treatment in closed-loop systems or methods
- A61B5/4839—Diagnosis combined with treatment in closed-loop systems or methods combined with drug delivery
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/68—Arrangements of detecting, measuring or recording means, e.g. sensors, in relation to patient
- A61B5/6846—Arrangements of detecting, measuring or recording means, e.g. sensors, in relation to patient specially adapted to be brought in contact with an internal body part, i.e. invasive
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/74—Details of notification to user or communication with user or patient ; user input means
- A61B5/742—Details of notification to user or communication with user or patient ; user input means using visual displays
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2250/00—Specially adapted for animals
Definitions
- a medical emergency such as an allergic reaction or an injury.
- a device includes a detector, a sensor, and a transceiver.
- the detector triggers a chemical reaction upon contact with a target substance in a user's body.
- the sensor detects when the chemical reaction occurs.
- the transceiver transmits an electronic signal containing a record of the chemical reaction to a user endpoint device.
- a device in another example, includes a processor and a computer-readable medium storing instructions which, when executed by the processor, cause the processor to perform operations.
- the operations include forwarding a first electronic signal received from a nanite deployed in a user's body to a remote server.
- the first electronic signal contains a record of a chemical reaction detected by the nanite in the user's body.
- the operations further include receiving a second electronic signal from the remote server.
- the second electronic signal contains an instruction for responding to a potential health risk indicated by the chemical reaction.
- the operations further include taking an action to mitigate the potential health risk based on the instruction.
- FIG. 1 illustrates an example network related to the present disclosure
- FIG. 2 illustrates an example of a nanite that may be used to detect a potential health risk
- FIG. 3 illustrates a flowchart of a first example method for detecting a potential health risk
- FIG. 4 illustrates a flowchart of a second example method for detecting a potential health risk
- FIG. 5 illustrates a flowchart of a third example method for detecting a potential health risk
- FIG. 6 depicts a high-level block diagram of a computing device specifically programmed to perform the functions described herein.
- the present disclosure detects potential health risks using nanorobotics.
- biomedical conditions such as diabetes, high cholesterol, allergies, hemophilia, and exposure to unwanted and/or unhealthy substances, among other conditions.
- many of these systems are subject to false results due to equipment degradation and failure, contamination, human error, or other factors.
- the response times of such systems may not be quick enough to allow treatment to be administered in a timely manner.
- ingestible, non-toxic nano-scale robotics also referred to as “nanorobotics” or “nanites”
- the nanites include a detection mechanism, which may be chemical in nature, as well as short-range transceivers which allow them to communicate and to share data with nearby computing devices.
- the nanites may further include a reservoir of medication and a dispensing mechanism for dispensing the medication.
- FIG. 1 illustrates an example network 100 , related to the present disclosure.
- the network 100 may be any type of communications network, such as for example, a traditional circuit switched network (CS) (e.g., a public switched telephone network (PSTN)) or an Internet Protocol (IP) network (e.g., an IP Multimedia Subsystem (IMS) network, an asynchronous transfer mode (ATM) network, a wireless network, a cellular network (e.g., 2G, 3G and the like), a long term evolution (LTE) network, and the like) related to the current disclosure.
- IP network is broadly defined as a network that uses Internet Protocol to exchange data packets.
- Additional exemplary IP networks include Voice over IP (VoIP) networks, Service over IP (SoIP) networks, and the like.
- VoIP Voice over IP
- SoIP Service over IP
- the network 100 may comprise a core network 102 .
- core network 102 may combine core network components of a cellular network with components of a triple play service network; where triple play services include telephone services, Internet services, and television services to subscribers.
- core network 102 may functionally comprise a fixed mobile convergence (FMC) network, e.g., an IP Multimedia Subsystem (IMS) network.
- FMC fixed mobile convergence
- IMS IP Multimedia Subsystem
- core network 102 may functionally comprise a telephony network, e.g., an Internet Protocol/Multi-Protocol Label Switching (IP/MPLS) backbone network utilizing Session Initiation Protocol (SIP) for circuit-switched and Voice over Internet Protocol (VoIP) telephony services.
- IP/MPLS Internet Protocol/Multi-Protocol Label Switching
- SIP Session Initiation Protocol
- VoIP Voice over Internet Protocol
- Core network 102 may also further comprise an Internet Service Provider (ISP) network.
- the core network 102 may include an application server (AS) 104 and a database (DB) 106 .
- AS application server
- DB database
- AS 104 and DB 106 are illustrated, it should be noted that any number of application servers 104 or databases 106 may be deployed.
- FIG. 1 various additional elements of core network 102 are omitted from FIG. 1 .
- the AS 104 may comprise a general purpose computer as illustrated in FIG. 6 and discussed below. In one embodiment, the AS 104 may perform the methods discussed below related to detecting potential health risks.
- the DB 106 may store data relating to user health.
- the DB 106 may store user profiles, which users can update dynamically at any time.
- User profiles may include contact information (e.g., mobile phone number, email address, etc.) for the user and/or the user's healthcare provider(s).
- User profiles may also include user health history information (e.g., medications taken, allergies, known medical conditions, measurements of weight, blood pressure, or other health-related metrics, etc.).
- User profiles may also store data transmitted by nanites in the associated users' systems or bodies. User profiles may be stored in encrypted form to protect user privacy.
- the access network 120 may be in communication with one or more user endpoint devices (also referred to as “endpoint devices” or “UE”) 108 and 110 , while the access network 122 may be in communication with one or more user endpoint devices 112 and 114 .
- Access networks 120 and 122 may transmit and receive communications between respective UEs 108 , 110 , 112 , and 114 and core network 102 relating to communications with web servers, AS 104 , and/or other servers via the Internet and/or other networks, and so forth.
- Each of the nanites 124 , 126 , 128 , or 130 may also include a transceiver for communicating with the UEs 108 , 110 , 112 , and 114 (e.g., over a near field communication protocol or other short range communication protocol).
- the nanites may further include a reservoir of medication and a dispensing mechanism for dispending the medication.
- the nanites 124 , 126 , 128 , or 130 may be configured as illustrated in FIG. 2 and discussed below
- any one or more of the user endpoint devices 108 , 110 , 112 , and 114 may host an operating system for presenting a user interface that may be used to send data to the AS 104 (e.g., signals from nanites 124 , 126 , 128 , or 130 or other data) and for reviewing data sent by the AS 104 (e.g., alerts, recommendations, etc.).
- data e.g., signals from nanites 124 , 126 , 128 , or 130 or other data
- reviewing data sent by the AS 104 e.g., alerts, recommendations, etc.
- FIG. 2 illustrates an example of a nanite that may be used to detect a potential health risk.
- Any of the nanites 124 , 126 , 128 , or 130 of FIG. 1 may be configured to include the elements of the nanite 200 illustrated in FIG. 2 .
- nanites configured as illustrated in FIG. 2 may be deployed to a user's system or body orally (e.g., by ingesting a pill or other comestible) or by injection. Nanites that are orally ingested may adhere to the inside of the user's mouth in order to detect substances as they enter the user's mouth.
- the detector 204 comprises a consumable substance that reacts with certain other substances in the user's system.
- the detector 204 may comprise a catalyst or enzyme that triggers a chemical reaction when it comes into contact with certain substances that may present or be indicative of an imminent health risk (e.g., drugs, allergens, antibodies, or pathogens. In one example, this chemical reaction exhausts the nanite's supply of the detector 204 .
- the precise material composition of the detector 204 may be selected to react with a specific substance of interest (e.g., a target substance).
- the reservoir 206 may contain a supply of medication or other substance used to treat certain health risks.
- the reservoir 204 may contain a supply of epinephrine to treat exposure of the user to an allergen, a supply of clotting factors used to treat a hemophiliac user who has sustained an open wound, or a supply of lactase to help a lactose-intolerant user's body break down lactose.
- the substrate 202 houses most of the non-consumable components of the nanite 200 .
- these components include a power source 208 , a sensor 210 , and a transceiver 212 .
- the sensor 210 comprises a device that is capable of detecting chemical reactions within a limited spatial range.
- the sensor 210 detects chemical reactions triggered by the detector 204 coming into contact with certain substances in the user's system or body.
- the sensor 210 is further configured to send signals to the transceiver 212 when it detects such chemical reactions.
- the sensor 210 is also able to detect when the nanite 200 is close to expiration (e.g., due to exhaustion of the detector 204 or the power source 208 ) and to send a signal to the transceiver 212 to alert it to the approaching expiration.
- the transceiver 212 includes at least a transmitter for transmitting the signals sent by the sensor 210 .
- the transmitter transmits the signals using a short range communication protocol, such as a near-field communication protocol.
- the transceiver 212 may also include a receiver. The receiver may receive signals containing instructions, such as instructions to dispense medication from the reservoir 206 .
- the nanite 200 may further include a small amount of local memory (not shown) that allows it to at least temporarily store signals from the detector 204 until they can be transmitted by the transceiver 212 .
- the nanite 200 may further comprise a shell 214 that at least temporarily encloses all or some of the substrate 202 , the detector 204 , and the reservoir 206 .
- the shell 214 may have a structure that allows the nanite 200 to adhere to a surface, such as the flesh inside of a user's mouth.
- the shell 214 may take the shape of a spiked ball, where the spikes help the nanite 200 to adhere to the surface.
- the method 300 begins in step 302 .
- a nanite having been ingested by a user, detects (e.g., via the sensor 210 of FIG. 2 ) a chemical reaction in the user's system.
- the chemical reaction may indicate that the user has been exposed to a potential health risk.
- the chemical reaction may be a reaction of a catalyst or enzyme with a substance (e.g., a drug or allergen) in the user's mouth.
- the chemical reaction may be a reaction of a catalyst or enzyme with a substance (e.g., oxygen, cholesterol, or glucose) in the user's bloodstream.
- a three-way handshake is used to establish a secure communication channel between the nanite and the user endpoint device before the first electronic signal is transmitted. This will protect the privacy of the information that is exchanged. Records of detected chemical reactions may be transmitted in real time upon detection (e.g., immediately upon detection, subject to any network latency), or they may be stored locally for a time and subsequently transmitted (e.g., upon request from the user endpoint device or according to a predefined transmission schedule).
- the nanite receives (e.g., via the transceiver 212 ) a second electronic signal from the user endpoint device.
- the second electronic signal may contain an instruction that instructs the nanite to take some action to counteract a potential health risk that has been detected as a result of the detected chemical reaction. For instance, if the potential health risk is exposure to an allergen, the instruction may instruct the nanite to dispense epinephrine. If the potential health risk is exposure to lactose, the instruction may instruct the nanite to dispense lactase to break down the lactose.
- the instruction may instruct the nanite to dispense a statin. If the potential health risk is a high or low blood glucose level, the instruction may instruct the nanite to dispense insulin. If the potential health risk is an open wound in a hemophiliac user, the instruction may instruct the nanite to dispense clotting factors.
- the nanite takes an action in accordance with the instruction extracted from the second electronic signal.
- the nanite may dispense a medication or other substance via the reservoir 206 in order to counteract a potential health risk, as discussed above.
- the nanite detects (e.g., via the sensor 210 ) that it is close to expiration. For instance, the nanite may detect that its supply of the detector 204 is exhausted or is close to being exhausted. The nanite may also detect that its power source 208 is low.
- the nanite transmits (e.g., via the transceiver 212 ) a third electronic signal to the user endpoint device.
- the third electronic signal contains a notification that the nanite is close to expiration. This notification will allow the user endpoint device to notify the user that it may be time to replenish his or her supply of nanites.
- the method 300 ends in step 318 .
- FIG. 4 illustrates a flowchart of a second example method 400 for detecting a potential health risk.
- the method 400 may be performed by a mobile device such as a mobile phone or a wearable smart device, e.g., one of the user endpoint devices 108 , 110 , 112 , or 114 illustrated in FIG. 1 .
- the method 400 may be performed by another device.
- any references in the discussion of the method 400 to the user endpoint devices 108 , 110 , 112 , and 114 of FIG. 1 are not intended to limit the means by which the method 400 may be performed.
- the method 400 begins in step 402 .
- the user endpoint device receives a first electronic signal from a nanite that is deployed in the user's system or body (e.g., in the user's mouth or bloodstream).
- the first electronic signal contains a record of a chemical reaction detected by the nanite, where the chemical reaction may indicate exposure of the user to a potential health risk.
- the first electronic signal is received using a short-range communication protocol, such as a near-field communication protocol.
- a three-way handshake may be used to establish a secure communication channel between the nanite and the user endpoint device before the first electronic signal is transmitted.
- step 406 the user endpoint device forwards the first electronic signal to a remote server, such as the AS 104 illustrated in FIG. 1 .
- the user endpoint device receives a second electronic signal from the remote server.
- the second electronic signal may contain an instruction meant to be forwarded to at least one nanite.
- the second electronic signal may also (or alternatively) contain an instruction meant for the user endpoint device.
- the user endpoint device forwards the second electronic signal to at least one nanite. For instance, if the second electronic signal contains an instruction that instructs the at least one nanite to take some sort of action (e.g., dispense a medication), then the user endpoint device would forward the second electronic signal to the at least one nanite so that the at least one nanite could receive the instruction and take action in a timely manner.
- some sort of action e.g., dispense a medication
- the user endpoint device takes an action in accordance with the second electronic signal.
- the second electronic signal may contain an instruction instructing the user endpoint device to alert the user that he or she has been exposed to a potential health risk.
- the user endpoint device may take action by displaying a message that notifies the user of the exposure and/or advises him or her to seek further medical assistance (e.g., by checking an application for more information or visiting a doctor).
- the method 400 ends in step 414 .
- FIG. 5 illustrates a flowchart of a third example method 500 for detecting a potential health risk.
- the method 500 may be performed by an application server, e.g., AS 104 illustrated in FIG. 1 .
- the method 500 may be performed by another device.
- any references in the discussion of the method 500 to the AS 104 of FIG. 1 are not intended to limit the means by which the method 500 may be performed.
- the method 500 begins in step 502 .
- the server receives a first electronic signal from a user endpoint device.
- the first electronic signal contains a record of a chemical reaction detected by nanite that is deployed in a user's system (e.g., in the user's mouth or bloodstream).
- step 506 the server sends a second electronic signal to the user endpoint device.
- the second electronic signal may contain an instruction meant to be forwarded to one or more nanites in the user's system (e.g., an instruction to dispense medication).
- the second electronic signal may also (or alternatively) contain an instruction meant for the user endpoint device (e.g., an instruction to display an alert).
- the server stores (e.g., in DB 106 of FIG. 1 ) information about the detected chemical reaction.
- the server may additionally store information about any instructions sent to nanites and/or user endpoint devices (e.g., as in step 506 ).
- step 504 If the server concludes in step 504 that the user has not been exposed to a potential health risk, then the method 500 proceeds directly to step 508 .
- storing the information about the detected chemical reaction may help the server to identify potential health risks in the future. For instance, this may help the server to detect when there is a spike in the concentration of a particular substance (e.g., glucose, cholesterol, etc.) in a user's bloodstream.
- a particular substance e.g., glucose, cholesterol, etc.
- the method 500 ends in step 510 .
- one or more steps of the methods 300 , 400 , or 500 may include a storing, displaying and/or outputting step as required for a particular application.
- any data, records, fields, and/or intermediate results discussed in the method can be stored, displayed and/or outputted to another device as required for a particular application.
- operations, steps, or blocks in FIG. 3, 4 , or 5 that recite a determining operation or involve a decision do not necessarily require that both branches of the determining operation be practiced. In other words, one of the branches of the determining operation can be deemed as an optional step.
- operations, steps or blocks of the above described method(s) can be combined, separated, and/or performed in a different order from that described above, without departing from the examples of the present disclosure.
- FIG. 6 depicts a high-level block diagram of a computing device specifically programmed to perform the functions described herein.
- any one or more components or devices illustrated in FIGS. 1 and 2 or described in connection with the methods 300 , 400 , or 500 may be implemented as the system 600 .
- a nanite such as may be used to perform the method 300
- a user endpoint device such as might be used to perform the method 400
- an application server such as might be used to perform the method 500
- the system 600 comprises a hardware processor element 602 , a memory 604 , a module 605 for detecting potential health risks, and various input/output (I/O) devices 606 .
- the hardware processor 602 may comprise, for example, a microprocessor, a central processing unit (CPU), or the like.
- the memory 604 may comprise, for example, random access memory (RAM), read only memory (ROM), a disk drive, an optical drive, a magnetic drive, and/or a Universal Serial Bus (USB) drive.
- the module 605 for detecting potential health risks may include circuitry and/or logic for performing special purpose functions relating to the monitoring, analyzing, and reporting of potential health risks.
- the input/output devices 606 may include, for example, a camera, a video camera, storage devices (including but not limited to, a tape drive, a floppy drive, a hard disk drive or a compact disk drive), a receiver, a transmitter, a speaker, a microphone, a transducer, a display, a speech synthesizer, a haptic device, an output port, or a user input device (such as a keyboard, a keypad, a mouse, and the like).
- storage devices including but not limited to, a tape drive, a floppy drive, a hard disk drive or a compact disk drive
- a receiver includes a transmitter, a speaker, a microphone, a transducer, a display, a speech synthesizer, a haptic device, an output port, or a user input device (such as a keyboard, a keypad, a mouse, and the like).
- the general-purpose computer may employ a plurality of processor elements.
- the general-purpose computer may employ a plurality of processor elements.
- the general-purpose computer of this Figure is intended to represent each of those multiple general-purpose computers.
- one or more hardware processors can be utilized in supporting a virtualized or shared computing environment.
- the virtualized computing environment may support one or more virtual machines representing computers, servers, or other computing devices. In such virtualized virtual machines, hardware components such as hardware processors and computer-readable storage devices may be virtualized or logically represented.
- the present disclosure can be implemented in software and/or in a combination of software and hardware, e.g., using application specific integrated circuits (ASIC), a programmable logic array (PLA), including a field-programmable gate array (FPGA), or a state machine deployed on a hardware device, a general purpose computer or any other hardware equivalents, e.g., computer readable instructions pertaining to the method(s) discussed above can be used to configure a hardware processor to perform the steps, functions and/or operations of the above disclosed method(s).
- ASIC application specific integrated circuits
- PDA programmable logic array
- FPGA field-programmable gate array
- instructions and data for the present module or process 605 for detecting potential health risks can be loaded into memory 604 and executed by hardware processor element 602 to implement the steps, functions or operations as discussed above in connection with the example methods 300 , 400 , or 500 .
- a hardware processor executes instructions to perform “operations,” this could include the hardware processor performing the operations directly and/or facilitating, directing, or cooperating with another hardware device or component (e.g., a co-processor and the like) to perform the operations.
- the processor executing the computer readable or software instructions relating to the above described method(s) can be perceived as a programmed processor or a specialized processor.
- the present module 605 for detecting potential health risks (including associated data structures) of the present disclosure can be stored on a tangible or physical (broadly non-transitory) computer-readable storage device or medium, e.g., volatile memory, non-volatile memory, ROM memory, RAM memory, magnetic or optical drive, device or diskette and the like.
- the computer-readable storage device may comprise any physical devices that provide the ability to store information such as data and/or instructions to be accessed by a processor or a computing device such as a computer or an application server.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Physics & Mathematics (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Pathology (AREA)
- Public Health (AREA)
- Medical Informatics (AREA)
- Heart & Thoracic Surgery (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Surgery (AREA)
- Biophysics (AREA)
- Chemical & Material Sciences (AREA)
- Computer Networks & Wireless Communication (AREA)
- Physiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Optics & Photonics (AREA)
- Spectroscopy & Molecular Physics (AREA)
- Electrochemistry (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Physics & Mathematics (AREA)
- Nanotechnology (AREA)
- General Business, Economics & Management (AREA)
- Epidemiology (AREA)
- Primary Health Care (AREA)
- Business, Economics & Management (AREA)
- Medical Treatment And Welfare Office Work (AREA)
- Measuring And Recording Apparatus For Diagnosis (AREA)
- Anesthesiology (AREA)
- Hematology (AREA)
- Vascular Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
Abstract
Description
- This application is a continuation of U.S. patent application Ser. No. 15/463,260, filed Mar. 20, 2017, now. U.S. Pat. No. 10,945,603, which is herein incorporated by reference in its entirety.
- The present disclosure relates generally to biomedical monitoring, and relates more particularly to devices, non-transitory computer-readable media, and methods for detecting health risks using nanorobotics.
- Various systems exist for monitoring and/or treating biomedical conditions. For instance, there are home testing kits for monitoring conditions such as diabetes and high cholesterol. There are also reactive agents and devices that can detect when unwanted or unhealthy substances (e.g., drugs) have been introduced into a person's food or drink. There are also devices for administering medication in the event of a medical emergency, such as an allergic reaction or an injury.
- In one example, the present disclosure describes a device, computer-readable medium, and method for detecting potential health risks using nanorobotics. For instance, in one example, a device includes a detector, a sensor, and a transceiver. The detector triggers a chemical reaction upon contact with a target substance in a user's body. The sensor detects when the chemical reaction occurs. The transceiver transmits an electronic signal containing a record of the chemical reaction to a user endpoint device.
- In another example, a method includes forwarding a first electronic signal received from a nanite deployed in a user's body to a remote server. The first electronic signal contains a record of a chemical reaction detected by the nanite in the user's body. The method further includes receiving a second electronic signal from the remote server. The second electronic signal contains an instruction for responding to a potential health risk indicated by the chemical reaction. The method further includes taking an action to mitigate the potential health risk based on the instruction.
- In another example, a device includes a processor and a computer-readable medium storing instructions which, when executed by the processor, cause the processor to perform operations. The operations include forwarding a first electronic signal received from a nanite deployed in a user's body to a remote server. The first electronic signal contains a record of a chemical reaction detected by the nanite in the user's body. The operations further include receiving a second electronic signal from the remote server. The second electronic signal contains an instruction for responding to a potential health risk indicated by the chemical reaction. The operations further include taking an action to mitigate the potential health risk based on the instruction.
- The teachings of the present disclosure can be readily understood by considering the following detailed description in conjunction with the accompanying drawings, in which:
-
FIG. 1 illustrates an example network related to the present disclosure; -
FIG. 2 illustrates an example of a nanite that may be used to detect a potential health risk; -
FIG. 3 illustrates a flowchart of a first example method for detecting a potential health risk; -
FIG. 4 illustrates a flowchart of a second example method for detecting a potential health risk; -
FIG. 5 illustrates a flowchart of a third example method for detecting a potential health risk; and -
FIG. 6 depicts a high-level block diagram of a computing device specifically programmed to perform the functions described herein. - To facilitate understanding, identical reference numerals have been used, where possible, to designate identical elements that are common to the figures.
- In one example, the present disclosure detects potential health risks using nanorobotics. As discussed above, various systems exist for monitoring and/or treating biomedical conditions, such as diabetes, high cholesterol, allergies, hemophilia, and exposure to unwanted and/or unhealthy substances, among other conditions. However, many of these systems are subject to false results due to equipment degradation and failure, contamination, human error, or other factors. Moreover, the response times of such systems may not be quick enough to allow treatment to be administered in a timely manner.
- Examples of the present disclosure use ingestible, non-toxic nano-scale robotics (also referred to as “nanorobotics” or “nanites”) to monitor biomedical conditions on an on-demand or continuous basis, and, in some cases, to administer treatments such as medications. The nanites include a detection mechanism, which may be chemical in nature, as well as short-range transceivers which allow them to communicate and to share data with nearby computing devices. In some examples, the nanites may further include a reservoir of medication and a dispensing mechanism for dispensing the medication.
- Moreover, although the disclosure is primarily describes a context in which the end user is human, it will be appreciated that the nanites of the present disclosure could also be deployed to monitor potential health risks to non-human users, such as animals. Since animals cannot communicate verbally with humans, this can make it difficult to diagnose the conditions of their health. Deploying nanites into their systems or bodies may help to identify some of these conditions in a timely manner (e.g., to detect when a dog has consumed chocolate or a poisonous plant).
- To better understand the present disclosure,
FIG. 1 illustrates anexample network 100, related to the present disclosure. Thenetwork 100 may be any type of communications network, such as for example, a traditional circuit switched network (CS) (e.g., a public switched telephone network (PSTN)) or an Internet Protocol (IP) network (e.g., an IP Multimedia Subsystem (IMS) network, an asynchronous transfer mode (ATM) network, a wireless network, a cellular network (e.g., 2G, 3G and the like), a long term evolution (LTE) network, and the like) related to the current disclosure. It should be noted that an IP network is broadly defined as a network that uses Internet Protocol to exchange data packets. Additional exemplary IP networks include Voice over IP (VoIP) networks, Service over IP (SoIP) networks, and the like. - In one example, the
network 100 may comprise acore network 102. In one example,core network 102 may combine core network components of a cellular network with components of a triple play service network; where triple play services include telephone services, Internet services, and television services to subscribers. For example,core network 102 may functionally comprise a fixed mobile convergence (FMC) network, e.g., an IP Multimedia Subsystem (IMS) network. In addition,core network 102 may functionally comprise a telephony network, e.g., an Internet Protocol/Multi-Protocol Label Switching (IP/MPLS) backbone network utilizing Session Initiation Protocol (SIP) for circuit-switched and Voice over Internet Protocol (VoIP) telephony services.Core network 102 may also further comprise an Internet Service Provider (ISP) network. In one embodiment, thecore network 102 may include an application server (AS) 104 and a database (DB) 106. Although only asingle AS 104 and asingle DB 106 are illustrated, it should be noted that any number ofapplication servers 104 ordatabases 106 may be deployed. Furthermore, for ease of illustration, various additional elements ofcore network 102 are omitted fromFIG. 1 . - In one embodiment, the AS 104 may comprise a general purpose computer as illustrated in
FIG. 6 and discussed below. In one embodiment, theAS 104 may perform the methods discussed below related to detecting potential health risks. - In one embodiment, the DB 106 may store data relating to user health. For example, the DB 106 may store user profiles, which users can update dynamically at any time. User profiles may include contact information (e.g., mobile phone number, email address, etc.) for the user and/or the user's healthcare provider(s). User profiles may also include user health history information (e.g., medications taken, allergies, known medical conditions, measurements of weight, blood pressure, or other health-related metrics, etc.). User profiles may also store data transmitted by nanites in the associated users' systems or bodies. User profiles may be stored in encrypted form to protect user privacy.
- The
core network 102 may be in communication with one or morewireless access networks access networks access networks core network 102 may provide a data service to subscribers viaaccess networks access networks core network 102 and theaccess networks - In one example, the
access network 120 may be in communication with one or more user endpoint devices (also referred to as “endpoint devices” or “UE”) 108 and 110, while theaccess network 122 may be in communication with one or moreuser endpoint devices Access networks respective UEs core network 102 relating to communications with web servers, AS 104, and/or other servers via the Internet and/or other networks, and so forth. - In one embodiment, the
user endpoint devices user endpoint devices FIG. 1 , any number of user endpoint devices may be deployed. - In one example, the
UEs more nanites nanites nanites UEs nanites FIG. 2 and discussed below - It should also be noted that as used herein, the terms “configure” and “reconfigure” may refer to programming or loading a computing device with computer-readable/computer-executable instructions, code, and/or programs, e.g., in a memory, which when executed by a processor of the computing device, may cause the computing device to perform various functions. Such terms may also encompass providing variables, data values, tables, objects, or other data structures or the like which may cause a computer device executing computer-readable instructions, code, and/or programs to function differently depending upon the values of the variables or other data structures that are provided. For example, any one or more of the
user endpoint devices nanites - Those skilled in the art will realize that the
network 100 has been simplified. For example, thenetwork 100 may include other network elements (not shown) such as border elements, routers, switches, policy servers, security devices, a content distribution network (CDN) and the like. Thenetwork 100 may also be expanded by including additional endpoint devices, access networks, network elements, application servers, etc. without altering the scope of the present disclosure. - To further aid in understanding the present disclosure,
FIG. 2 illustrates an example of a nanite that may be used to detect a potential health risk. Any of thenanites FIG. 1 may be configured to include the elements of thenanite 200 illustrated inFIG. 2 . In one example, nanites configured as illustrated inFIG. 2 may be deployed to a user's system or body orally (e.g., by ingesting a pill or other comestible) or by injection. Nanites that are orally ingested may adhere to the inside of the user's mouth in order to detect substances as they enter the user's mouth. Nanites that are orally ingested or deployed via injection may make their way into the user's bloodstream in order to detect antibodies, pathogens, or other substances in the user's blood. Nanites may exit the user's body via the same natural processes that remove dead blood cells. - As illustrated in
FIG. 2 , thenanite 200 generally comprises asubstrate 202, adetector 204, and areservoir 206. Thesubstrate 202 houses most of the non-consumable components of the nanite (e.g., power sources and circuitry), while thedetector 204 and thereservoir 206 house consumable components that are used up in the detection and treatment of potential health risks. Thesubstrate 202,detector 204, andreservoir 206 may be coupled together for ease of deployment and operation. - In one example, the
detector 204 comprises a consumable substance that reacts with certain other substances in the user's system. For instance, thedetector 204 may comprise a catalyst or enzyme that triggers a chemical reaction when it comes into contact with certain substances that may present or be indicative of an imminent health risk (e.g., drugs, allergens, antibodies, or pathogens. In one example, this chemical reaction exhausts the nanite's supply of thedetector 204. The precise material composition of thedetector 204 may be selected to react with a specific substance of interest (e.g., a target substance). - The
reservoir 206 may contain a supply of medication or other substance used to treat certain health risks. For instance, thereservoir 204 may contain a supply of epinephrine to treat exposure of the user to an allergen, a supply of clotting factors used to treat a hemophiliac user who has sustained an open wound, or a supply of lactase to help a lactose-intolerant user's body break down lactose. - As discussed above, the
substrate 202 houses most of the non-consumable components of thenanite 200. In one example, these components include apower source 208, asensor 210, and atransceiver 212. - The
power source 208 provides power (e.g., electrical power) to one or both of thesensor 210 and thetransceiver 212. In one example, thepower source 208 comprises a non-toxic battery that stores a limited amount of energy. In another example, thepower source 208 comprises a non-toxic battery that stores converted energy from a renewable source. For instance, the battery may comprise a thermoelectric generator that converts the user's body heat into energy, or a photovoltaic cell that converts the sun's infrared radiation (absorbed by the user's skin) into energy. In a further example, a battery based on a thermoelectric generator may also be capable of regulating the user's body temperature if it can absorb enough heat. - The
sensor 210 comprises a device that is capable of detecting chemical reactions within a limited spatial range. In particular, thesensor 210 detects chemical reactions triggered by thedetector 204 coming into contact with certain substances in the user's system or body. Thesensor 210 is further configured to send signals to thetransceiver 212 when it detects such chemical reactions. In a further example, thesensor 210 is also able to detect when thenanite 200 is close to expiration (e.g., due to exhaustion of thedetector 204 or the power source 208) and to send a signal to thetransceiver 212 to alert it to the approaching expiration. - The
transceiver 212 includes at least a transmitter for transmitting the signals sent by thesensor 210. In one example, the transmitter transmits the signals using a short range communication protocol, such as a near-field communication protocol. In a further example, thetransceiver 212 may also include a receiver. The receiver may receive signals containing instructions, such as instructions to dispense medication from thereservoir 206. - In some examples, the
nanite 200 may further include a small amount of local memory (not shown) that allows it to at least temporarily store signals from thedetector 204 until they can be transmitted by thetransceiver 212. - In one example, the
nanite 200 may further comprise ashell 214 that at least temporarily encloses all or some of thesubstrate 202, thedetector 204, and thereservoir 206. Theshell 214 may have a structure that allows thenanite 200 to adhere to a surface, such as the flesh inside of a user's mouth. For instance, theshell 214 may take the shape of a spiked ball, where the spikes help thenanite 200 to adhere to the surface. -
FIG. 3 illustrates a flowchart of afirst example method 300 for detecting a potential health risk. In one example, themethod 300 may be performed by a nanite, e.g., one of thenanites FIG. 1 or thenanite 200 illustrated inFIG. 2 . However, any references in the discussion of themethod 300 to thenanites FIG. 1 or thenanite 200 ofFIG. 2 are not intended to limit the means by which themethod 300 may be performed. - The
method 300 begins instep 302. Instep 304, a nanite, having been ingested by a user, detects (e.g., via thesensor 210 ofFIG. 2 ) a chemical reaction in the user's system. The chemical reaction may indicate that the user has been exposed to a potential health risk. In one example, the chemical reaction may be a reaction of a catalyst or enzyme with a substance (e.g., a drug or allergen) in the user's mouth. In another example, the chemical reaction may be a reaction of a catalyst or enzyme with a substance (e.g., oxygen, cholesterol, or glucose) in the user's bloodstream. - In optional step 306 (illustrated in phantom), the nanite stores a record of the detected chemical reaction (e.g., time of detection, magnitude of chemical reaction, etc.). This record may be stored in a local storage of the nanite.
- In
step 308, the nanite transmits (e.g., via the transceiver 212) the record of the detected chemical reaction in a first electronic signal to a user endpoint device that is within communication range of the nanite. In one example, the user endpoint device is a mobile communication device, such as a mobile phone or a wearable smart device (e.g., a smart watch or fitness tracker). For instance, the user endpoint device may be one of theUEs FIG. 1 . In one example, the first electronic signal is transmitted using a short-range communication protocol, such as a near-field communication protocol. In a further example, a three-way handshake is used to establish a secure communication channel between the nanite and the user endpoint device before the first electronic signal is transmitted. This will protect the privacy of the information that is exchanged. Records of detected chemical reactions may be transmitted in real time upon detection (e.g., immediately upon detection, subject to any network latency), or they may be stored locally for a time and subsequently transmitted (e.g., upon request from the user endpoint device or according to a predefined transmission schedule). - In optional step 310 (illustrated in phantom), the nanite receives (e.g., via the transceiver 212) a second electronic signal from the user endpoint device. The second electronic signal may contain an instruction that instructs the nanite to take some action to counteract a potential health risk that has been detected as a result of the detected chemical reaction. For instance, if the potential health risk is exposure to an allergen, the instruction may instruct the nanite to dispense epinephrine. If the potential health risk is exposure to lactose, the instruction may instruct the nanite to dispense lactase to break down the lactose. If the potential health risk is a high cholesterol level, the instruction may instruct the nanite to dispense a statin. If the potential health risk is a high or low blood glucose level, the instruction may instruct the nanite to dispense insulin. If the potential health risk is an open wound in a hemophiliac user, the instruction may instruct the nanite to dispense clotting factors.
- In optional step 312 (illustrated in phantom), the nanite takes an action in accordance with the instruction extracted from the second electronic signal. For instance, the nanite may dispense a medication or other substance via the
reservoir 206 in order to counteract a potential health risk, as discussed above. - In optional step 314 (illustrated in phantom), the nanite detects (e.g., via the sensor 210) that it is close to expiration. For instance, the nanite may detect that its supply of the
detector 204 is exhausted or is close to being exhausted. The nanite may also detect that itspower source 208 is low. - In optional step 316 (illustrated in phantom), the nanite transmits (e.g., via the transceiver 212) a third electronic signal to the user endpoint device. The third electronic signal contains a notification that the nanite is close to expiration. This notification will allow the user endpoint device to notify the user that it may be time to replenish his or her supply of nanites.
- The
method 300 ends instep 318. -
FIG. 4 illustrates a flowchart of asecond example method 400 for detecting a potential health risk. In one example, themethod 400 may be performed by a mobile device such as a mobile phone or a wearable smart device, e.g., one of theuser endpoint devices FIG. 1 . However, in other examples, themethod 400 may be performed by another device. As such, any references in the discussion of themethod 400 to theuser endpoint devices FIG. 1 are not intended to limit the means by which themethod 400 may be performed. - The
method 400 begins instep 402. Instep 404, the user endpoint device receives a first electronic signal from a nanite that is deployed in the user's system or body (e.g., in the user's mouth or bloodstream). In one example, the first electronic signal contains a record of a chemical reaction detected by the nanite, where the chemical reaction may indicate exposure of the user to a potential health risk. In one example, the first electronic signal is received using a short-range communication protocol, such as a near-field communication protocol. As discussed above, a three-way handshake may be used to establish a secure communication channel between the nanite and the user endpoint device before the first electronic signal is transmitted. - In
step 406, the user endpoint device forwards the first electronic signal to a remote server, such as theAS 104 illustrated inFIG. 1 . - In
step 408, the user endpoint device receives a second electronic signal from the remote server. The second electronic signal may contain an instruction meant to be forwarded to at least one nanite. The second electronic signal may also (or alternatively) contain an instruction meant for the user endpoint device. - In optional step 410 (illustrated in phantom), the user endpoint device forwards the second electronic signal to at least one nanite. For instance, if the second electronic signal contains an instruction that instructs the at least one nanite to take some sort of action (e.g., dispense a medication), then the user endpoint device would forward the second electronic signal to the at least one nanite so that the at least one nanite could receive the instruction and take action in a timely manner.
- In optional step 412 (illustrated in phantom), the user endpoint device takes an action in accordance with the second electronic signal. For instance, the second electronic signal may contain an instruction instructing the user endpoint device to alert the user that he or she has been exposed to a potential health risk. Thus, the user endpoint device may take action by displaying a message that notifies the user of the exposure and/or advises him or her to seek further medical assistance (e.g., by checking an application for more information or visiting a doctor).
- The
method 400 ends instep 414. -
FIG. 5 illustrates a flowchart of athird example method 500 for detecting a potential health risk. In one example, themethod 500 may be performed by an application server, e.g., AS 104 illustrated inFIG. 1 . However, in other examples, themethod 500 may be performed by another device. As such, any references in the discussion of themethod 500 to theAS 104 ofFIG. 1 are not intended to limit the means by which themethod 500 may be performed. - The
method 500 begins instep 502. Instep 504, the server receives a first electronic signal from a user endpoint device. The first electronic signal contains a record of a chemical reaction detected by nanite that is deployed in a user's system (e.g., in the user's mouth or bloodstream). - In
step 502, the server determines whether the chemical reaction indicates that the user has been exposed to a potential health risk. For instance, the server may determine, based on the information in the record of the chemical reaction, whether it is more likely than not that the user's health is at risk. In one example, the determination is based on a single record of a chemical reaction (e.g., a single record indicating the presence of an allergen in the user's system or body). In another example, the determination may be based on the cumulative information contained in multiple records of chemical reactions recorded by one or more nanites in the user's system or body. For instance, the server could determine that the concentration of a particular substance (e.g., cholesterol, alcohol, glucose) in a user's bloodstream is higher than is healthy based on multiple reports of the presence of that substance over a period of time. - If the server concludes in
step 504 that the user has been exposed to a potential health risk, then themethod 500 proceeds to step 506. Instep 506, the server sends a second electronic signal to the user endpoint device. The second electronic signal may contain an instruction meant to be forwarded to one or more nanites in the user's system (e.g., an instruction to dispense medication). The second electronic signal may also (or alternatively) contain an instruction meant for the user endpoint device (e.g., an instruction to display an alert). - In
step 508, the server stores (e.g., inDB 106 ofFIG. 1 ) information about the detected chemical reaction. The server may additionally store information about any instructions sent to nanites and/or user endpoint devices (e.g., as in step 506). - If the server concludes in
step 504 that the user has not been exposed to a potential health risk, then themethod 500 proceeds directly to step 508. In this case, storing the information about the detected chemical reaction may help the server to identify potential health risks in the future. For instance, this may help the server to detect when there is a spike in the concentration of a particular substance (e.g., glucose, cholesterol, etc.) in a user's bloodstream. - The
method 500 ends in step 510. - Although not expressly specified above, one or more steps of the
methods FIG. 3, 4 , or 5 that recite a determining operation or involve a decision do not necessarily require that both branches of the determining operation be practiced. In other words, one of the branches of the determining operation can be deemed as an optional step. Furthermore, operations, steps or blocks of the above described method(s) can be combined, separated, and/or performed in a different order from that described above, without departing from the examples of the present disclosure. -
FIG. 6 depicts a high-level block diagram of a computing device specifically programmed to perform the functions described herein. For example, any one or more components or devices illustrated inFIGS. 1 and 2 or described in connection with themethods system 600. For instance, a nanite (such as may be used to perform the method 300), a user endpoint device (such as might be used to perform the method 400) or an application server (such as might be used to perform the method 500) could be implemented as illustrated inFIG. 6 . - As depicted in
FIG. 6 , thesystem 600 comprises ahardware processor element 602, amemory 604, amodule 605 for detecting potential health risks, and various input/output (I/O)devices 606. - The
hardware processor 602 may comprise, for example, a microprocessor, a central processing unit (CPU), or the like. Thememory 604 may comprise, for example, random access memory (RAM), read only memory (ROM), a disk drive, an optical drive, a magnetic drive, and/or a Universal Serial Bus (USB) drive. Themodule 605 for detecting potential health risks may include circuitry and/or logic for performing special purpose functions relating to the monitoring, analyzing, and reporting of potential health risks. The input/output devices 606 may include, for example, a camera, a video camera, storage devices (including but not limited to, a tape drive, a floppy drive, a hard disk drive or a compact disk drive), a receiver, a transmitter, a speaker, a microphone, a transducer, a display, a speech synthesizer, a haptic device, an output port, or a user input device (such as a keyboard, a keypad, a mouse, and the like). - Although only one processor element is shown, it should be noted that the general-purpose computer may employ a plurality of processor elements. Furthermore, although only one general-purpose computer is shown in the Figure, if the method(s) as discussed above is implemented in a distributed or parallel manner for a particular illustrative example, i.e., the steps of the above method(s) or the entire method(s) are implemented across multiple or parallel general-purpose computers, then the general-purpose computer of this Figure is intended to represent each of those multiple general-purpose computers. Furthermore, one or more hardware processors can be utilized in supporting a virtualized or shared computing environment. The virtualized computing environment may support one or more virtual machines representing computers, servers, or other computing devices. In such virtualized virtual machines, hardware components such as hardware processors and computer-readable storage devices may be virtualized or logically represented.
- It should be noted that the present disclosure can be implemented in software and/or in a combination of software and hardware, e.g., using application specific integrated circuits (ASIC), a programmable logic array (PLA), including a field-programmable gate array (FPGA), or a state machine deployed on a hardware device, a general purpose computer or any other hardware equivalents, e.g., computer readable instructions pertaining to the method(s) discussed above can be used to configure a hardware processor to perform the steps, functions and/or operations of the above disclosed method(s). In one example, instructions and data for the present module or
process 605 for detecting potential health risks (e.g., a software program comprising computer-executable instructions) can be loaded intomemory 604 and executed byhardware processor element 602 to implement the steps, functions or operations as discussed above in connection with theexample methods - The processor executing the computer readable or software instructions relating to the above described method(s) can be perceived as a programmed processor or a specialized processor. As such, the
present module 605 for detecting potential health risks (including associated data structures) of the present disclosure can be stored on a tangible or physical (broadly non-transitory) computer-readable storage device or medium, e.g., volatile memory, non-volatile memory, ROM memory, RAM memory, magnetic or optical drive, device or diskette and the like. More specifically, the computer-readable storage device may comprise any physical devices that provide the ability to store information such as data and/or instructions to be accessed by a processor or a computing device such as a computer or an application server. - While various examples have been described above, it should be understood that they have been presented by way of example only, and not limitation. Thus, the breadth and scope of a preferred example should not be limited by any of the above-described example examples, but should be defined only in accordance with the following claims and their equivalents.
Claims (20)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US17/202,314 US20210196123A1 (en) | 2017-03-20 | 2021-03-15 | Detecting potential health risks using nanorobotics |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US15/463,260 US10945603B2 (en) | 2017-03-20 | 2017-03-20 | Detecting potential health risks using nanorobotics |
US17/202,314 US20210196123A1 (en) | 2017-03-20 | 2021-03-15 | Detecting potential health risks using nanorobotics |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US15/463,260 Continuation US10945603B2 (en) | 2017-03-20 | 2017-03-20 | Detecting potential health risks using nanorobotics |
Publications (1)
Publication Number | Publication Date |
---|---|
US20210196123A1 true US20210196123A1 (en) | 2021-07-01 |
Family
ID=63521355
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US15/463,260 Active 2038-06-30 US10945603B2 (en) | 2017-03-20 | 2017-03-20 | Detecting potential health risks using nanorobotics |
US17/202,314 Abandoned US20210196123A1 (en) | 2017-03-20 | 2021-03-15 | Detecting potential health risks using nanorobotics |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US15/463,260 Active 2038-06-30 US10945603B2 (en) | 2017-03-20 | 2017-03-20 | Detecting potential health risks using nanorobotics |
Country Status (1)
Country | Link |
---|---|
US (2) | US10945603B2 (en) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3578095A1 (en) * | 2018-06-07 | 2019-12-11 | Koninklijke Philips N.V. | An allergen warning system and method |
CN111419239B (en) * | 2020-04-15 | 2023-01-24 | 江苏食品药品职业技术学院 | Blood amino acid and carnitine quantitative determination device based on electromagnetic control |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20160287152A1 (en) * | 2015-03-30 | 2016-10-06 | Verily Life Sciences Llc | Functionalized Nanoparticles, Methods and In Vivo Diagnostic System |
US20180103879A1 (en) * | 2016-10-18 | 2018-04-19 | Senseonics, Incorporated | Real time assessement of sensor performance and prediction of the end of the functional life of an implanted sensor |
Family Cites Families (32)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6632175B1 (en) | 2000-11-08 | 2003-10-14 | Hewlett-Packard Development Company, L.P. | Swallowable data recorder capsule medical device |
US9393396B2 (en) | 2002-02-14 | 2016-07-19 | Gholam A. Peyman | Method and composition for hyperthermally treating cells |
WO2003070961A1 (en) | 2002-02-15 | 2003-08-28 | Diversa Corporation | Chimeric cannulae proteins, nucleic acids encoding them and methods for making and using them |
US7354433B2 (en) | 2003-02-28 | 2008-04-08 | Advanced Light Technologies, Llc | Disinfection, destruction of neoplastic growth, and sterilization by differential absorption of electromagnetic energy |
US7399400B2 (en) * | 2003-09-30 | 2008-07-15 | Nano-Proprietary, Inc. | Nanobiosensor and carbon nanotube thin film transistors |
US20060252143A1 (en) * | 2005-05-05 | 2006-11-09 | Lsi Logic Corporation | High resolution semiconductor bio-chip with configuration sensing flexibility |
US9067047B2 (en) * | 2005-11-09 | 2015-06-30 | The Invention Science Fund I, Llc | Injectable controlled release fluid delivery system |
US9101279B2 (en) | 2006-02-15 | 2015-08-11 | Virtual Video Reality By Ritchey, Llc | Mobile user borne brain activity data and surrounding environment data correlation system |
ATE544490T1 (en) | 2006-06-23 | 2012-02-15 | Koninkl Philips Electronics Nv | MEDICATION DISPENSING SYSTEM |
US20090214474A1 (en) | 2006-11-01 | 2009-08-27 | Barbara Brooke Jennings | Compounds, methods, and treatments for abnormal signaling pathways for prenatal and postnatal development |
US20080270097A1 (en) | 2006-11-13 | 2008-10-30 | Solomon Research Llc | System and methods for immunocomputing applied to collectives of nanorobots |
US7921384B2 (en) | 2006-11-13 | 2011-04-05 | Neal Solomon | System, methods and apparatuses for integrated circuits for nanorobotics |
US20080241065A1 (en) | 2007-03-27 | 2008-10-02 | Benaron David A | Systems and methods for the detection and analysis of in vivo circulating cells, entities, and nanobots |
WO2009064964A2 (en) * | 2007-11-15 | 2009-05-22 | The University Of California | Switchable nano-vehicle delivery systems, and methods for making and using them |
US8200310B2 (en) | 2007-11-19 | 2012-06-12 | University Of Southern California | Spinal injury imaging by magnetically levitated sensors |
EP2274090A4 (en) | 2008-01-03 | 2011-09-21 | Lockheed Corp | Nano-getter device |
US20100132469A1 (en) | 2008-12-01 | 2010-06-03 | University Of South Carolina | Nano-PWAS: Structurally Integrated Thin-Film Active Sensors for Structural Health Monitoring |
US20100204676A1 (en) | 2008-12-23 | 2010-08-12 | Cardullo Mario W | Method and apparatus for chemical detection and release |
EP2409287A1 (en) | 2009-03-17 | 2012-01-25 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Teleoperation method and human robot interface for remote control of a machine by a human operator |
US8497777B2 (en) * | 2009-04-15 | 2013-07-30 | Abbott Diabetes Care Inc. | Analyte monitoring system having an alert |
KR101040454B1 (en) | 2009-08-10 | 2011-06-09 | 성균관대학교산학협력단 | Micro robot for Emergency Measures |
DE102010009017A1 (en) | 2009-08-31 | 2011-03-10 | Siemens Aktiengesellschaft | Process for the formation of an endovascular treatment adjuvant by means of self-assembling, catomeres (Cat) nanorobots and associated system |
AU2010302270B2 (en) | 2009-09-30 | 2014-11-27 | Healthwatch Ltd. | Continuous non-interfering health monitoring and alert system |
US8768501B2 (en) | 2010-05-02 | 2014-07-01 | Max-Planck-Gesellschaft zur Foerderung der Wissenscaften e.V. (MPG) | Magnetic nanostructured propellers |
US20120072230A1 (en) | 2010-09-16 | 2012-03-22 | International Business Machines Corporation | Identification and nullification of substances |
EP2912088B1 (en) | 2012-10-24 | 2019-09-18 | KCI Licensing, Inc. | Sulfhydryl-functionalized polymeric compositions for medical devices |
US20140218537A1 (en) | 2013-02-06 | 2014-08-07 | Michael Nepo | System and method for disseminating information and implementing medical interventions to facilitate the safe emergence of users from crises |
US9970040B2 (en) | 2013-09-26 | 2018-05-15 | Massachusetts Institute Of Technology | Engineering DNA assembly in vivo and methods of making and using the reverse transcriptase technology |
US9662392B2 (en) * | 2014-06-03 | 2017-05-30 | Pop Test Abuse Deterrent Technology Llc | Drug device configured for wireless communication |
JP2016014074A (en) | 2014-06-19 | 2016-01-28 | 国立研究開発法人物質・材料研究機構 | Sensor, molecular machine and controller added to programmable nano-robot |
CA2875578A1 (en) | 2014-12-24 | 2016-06-24 | Stephan HEATH | Systems, computer media, and methods for using electromagnetic frequency (emf) identification (id) devices for monitoring, collection, analysis, use and tracking of personal, medical, transaction, and location data for one or more individuals |
US20170087299A1 (en) * | 2015-09-25 | 2017-03-30 | Intel Corporation | Carrier apparatus to deliver a substance and methods thereof |
-
2017
- 2017-03-20 US US15/463,260 patent/US10945603B2/en active Active
-
2021
- 2021-03-15 US US17/202,314 patent/US20210196123A1/en not_active Abandoned
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20160287152A1 (en) * | 2015-03-30 | 2016-10-06 | Verily Life Sciences Llc | Functionalized Nanoparticles, Methods and In Vivo Diagnostic System |
US20180103879A1 (en) * | 2016-10-18 | 2018-04-19 | Senseonics, Incorporated | Real time assessement of sensor performance and prediction of the end of the functional life of an implanted sensor |
Also Published As
Publication number | Publication date |
---|---|
US10945603B2 (en) | 2021-03-16 |
US20180263494A1 (en) | 2018-09-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US10999717B1 (en) | Message analysis application and response system | |
US20210098110A1 (en) | Digital Health Wellbeing | |
RU2571590C2 (en) | Remote monitoring system for monitoring medical devices via wireless communication systems | |
CN104969229B (en) | It is used for transmission system, the method and apparatus of data | |
US20210196123A1 (en) | Detecting potential health risks using nanorobotics | |
JP2015512175A (en) | Medical device remote monitoring system and method | |
Wu et al. | An interactive telecare system enhanced with IoT technology | |
US10395502B2 (en) | Smart mobility assistance device | |
US20190191024A1 (en) | Method and apparatus for dynamic configuration of a multiprocessor health data system | |
US10129348B2 (en) | Method and apparatus for modifying behavior of a user via a network | |
Schario et al. | Chatbot-assisted care management | |
Manirabona et al. | A 4-tiers architecture for mobile WBAN based health remote monitoring system | |
Triantafyllidis et al. | Framework of sensor‐based monitoring for pervasive patient care | |
Isakovic et al. | The Role of mHealth applications in societal and social challenges of the future | |
CN109243592B (en) | Medical project abnormal use detection method and related device based on artificial intelligence | |
US20210020290A1 (en) | Method and apparatus for initiating a medicine control action | |
Xiao et al. | Wireless telemedicine and m-health: technologies, applications and research issues | |
US10163314B2 (en) | Programmable devices to generate alerts based upon detection of physical objects | |
De Rolt et al. | COLLEGA middleware for the management of participatory Mobile Health Communities | |
CN107147638A (en) | The medical data Transmission system and method for dynamic encryption | |
Zinner et al. | Matching requirements for ambient assisted living and enhanced living environments with networking technologies | |
Alshareef et al. | First responder help facilitated by the mobile cloud | |
KR101797849B1 (en) | System for providing medical service | |
Powell et al. | To boldly go where no case manager has gone before: Remote patient monitoring and beyond | |
Mihuba et al. | Design of Telemedicine System Based on Mobile Terminal |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: AT&T INTELLECTUAL PROPERTY I, L.P., GEORGIA Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:YOO, BRIAN;RINALDI, VICTORIA;KAJUR, HARISH VENKATA;AND OTHERS;SIGNING DATES FROM 20170308 TO 20170828;REEL/FRAME:055630/0594 |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: APPLICATION DISPATCHED FROM PREEXAM, NOT YET DOCKETED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: FINAL REJECTION MAILED |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |